M2 PRESSWIRE-May 16, 2017-Janus Kinase (JAK) Inhibitors – Competitive Landscape, Pipeline and Market Analysis – 2017
(C)1994-2017 M2 COMMUNICATIONS
RDATE:16052017
Dublin – Research and Markets has announced the addition of the Janus Kinase (JAK) Inhibitors – Competitive Landscape, Pipeline and Market Analysis – 2017 report to their offering.
Janus Kinase Inhibitor (JAK) Inhibitors-Competitive Landscape, Technology and Pipeline Analysis, 2017 provides comprehensive insights about pipeline drugs across this indication. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Janus Kinase (JAK) Inhibitors. This report provides information on the therapeutic development based on the Janus Kinase (JAK) Inhibitorsdealing with all the pipeline drugs, comparative analysis of Janus Kinase (JAK) Inhibitorsat various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.
Key Topics Covered:
Executive Summary
Executive Summary Snapshot
Overview
Janus kinase Inhibitors (JAK Inhibitors)
Mechanism of Action
JAK Inhibitors Market Analysis
Collaborations and Deals
Acquisition Deals
Designations Analysis
Market Drivers
Market Barriers
Pipeline Therapeutics
Companies Involved
Therapeutics under Development by Companies
Marketed and Pre-registration Stage Products
Marketed Drugs
Late Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Preclinical Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant Products
Comparative Analysis
Companies involved in Therapeutics Development
SWOT Analysis for JAK inhibitors
Appendix
Methodology
Consulting Services
About Us
Contact Us
Disclaimer
List of Tables
Table: Collaboration and Deal Values for JAK Inhibitors
Table: Acquisition deals for the development of JAK Inhibitors
Table: Number of Products Under Development for Janus Kinase (JAK) Inhibitors
Table: Number of Products under Development by Companies
Table: Marketed and Pre-registration Stage Products
Table: Late Stage Products (Phase III)
Table: Mid Stage Products (Phase II)
Table: Early Stage Products (Phase I)
Table: Preclinical Products
Table: Assessment by Monotherapy Products
Table: Assessment by Route Of Administration
Table: Assessment by Stage and Route Of Administration
Table: Assessment by Molecule Type
Table: Assessment by Stage and Molecule Type
Table: Dormant Products
List of Figures
Figure: Number of Products under Development for JAK Inhibitors
Figure: Number of Companies under acquisition for JAK Inhibitors
Figure: Number of Companies under acquisition for JAK Inhibitors
Figure: Number of Products under Development for Janus Kinase (JAK) Inhibitors
Figure: Number of Products under Development for JAK Inhibitor
Figure: Marketed and Pre-registration Stage Products
Figure: Late Stage Products (Phase III)
Figure: Mid Stage Products (Phase II)
Figure: Early Stage Products (Phase I)
Figure: Preclinical Products
Figure: Number of Products under Development forJAK Inhibitors
Figure: Assessment by Route of Administration
Figure: Assessment by Stage and Molecule Type
Figure: Assessment by Molecule Type
Figure: Assessment by Stage and Molecule Type
Figure: Dormant Products
For more information about this report visit http://www.researchandmarkets.com/research/kt7r7p/janus_kinase
About Research and Markets
Research and Markets is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.